Get the Stockscreener App
1.50
13.64%
0.18
Sunshine Biopharma Inc stock is traded at $1.50, with a volume of 369.95K.
It is up +13.64% in the last 24 hours and up +22.95% over the past month.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
See More
Previous Close:
$1.32
Open:
$1.32
24h Volume:
369.95K
Relative Volume:
0.28
Market Cap:
$5.46M
Revenue:
$32.96M
Net Income/Loss:
$-4.23M
P/E Ratio:
-0.00966
EPS:
-155.3294
Net Cash Flow:
$-14.00M
1W Performance:
+20.00%
1M Performance:
+22.95%
6M Performance:
-36.03%
1Y Performance:
-91.57%
1-Day Range:
$1.32
$1.54
1-Week Range:
$1.28
$1.54
52-Week Range:
$1.1693
$21.00
Sunshine Biopharma Inc Stock (SBFM) Company Profile
Name
Sunshine Biopharma Inc
Sector
Phone
954-515-0810
Address
333 LAS OLAS WAY, FORT LAUDERDALE
Compare SBFM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SBFM
Sunshine Biopharma Inc
|
1.50 | 4.54M | 32.96M | -4.23M | -14.00M | -155.33 |
|
HLN
Haleon Plc Adr
|
10.80 | 48.39B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
163.04 | 70.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.85 | 3.54M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.11 | 45.20B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.94 | 19.42B | 16.54B | -1.64B | 749.00M | -1.45 |
Sunshine Biopharma Inc Stock (SBFM) Latest News
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year | SBFM Stock News - GuruFocus
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year - ACCESS Newswire
Sunshine Biopharma Reports Double-Digit Growth: Q1 Revenue Jumps 18% as Pipeline Expands with 6 New Drugs - Stock Titan
Sunshine Biopharma (NASDAQ:SBFM) Stock Price Up 8% – Here’s Why - Defense World
Sunshine Biopharma launches generic antipsychotic drug - Investing.com Australia
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia - GuruFocus
Sunshine Biopharma (SBFM) Unveils Generic Antipsychotic Drug in Canada | SBFM Stock News - GuruFocus
Sunshine Biopharma launches generic antipsychotic drug By Investing.com - Investing.com Canada
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market - ACCESS Newswire
Sunshine Biopharma Challenges $1.2B Antipsychotic Market With New Generic Latuda Alternative - Stock Titan
Certain Warrants of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2025. - marketscreener.com
Sunshine Biopharma Inc’s Market Journey: Closing Weak at 1.84, Down -18.22 - DWinneX
Sunshine Biopharma (NASDAQ:SBFMW) Stock Price Down 4.5% – Here’s Why - Defense World
There is no doubt that Sunshine Biopharma Inc (SBFM) ticks all the boxes. - Sete News
Sunshine Becomes Latest To Compete On Everolimus In Canada - insights.citeline.com
Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug - Asianet Newsable
Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug By Stocktwits - Investing.com India
SBFM Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Sunshine Biopharma enters Canadian generic drug market with Everolimus By Investing.com - Investing.com South Africa
Press Release Distribution & PR Platform - ACCESS Newswire
SBFM’s valuation metrics: A comprehensive analysis - uspostnews.com
Sunshine Biopharma (SBFM) Finalizes $2.46 Million Stock Offering - GuruFocus
Sunshine Biopharma Unit Rolls Out Afinitor Alternative Everolimus in Canadian Market - marketscreener.com
Sunshine Biopharma enters Canadian generic drug market with Everolimus - Investing.com
Sunshine Biopharma (SBFM) Launches Generic Everolimus in Canada | SBFM Stock News - GuruFocus
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion | SBFM Stock News - GuruFocus
Major Cancer Treatment Everolimus Enters Canadian Market: Multiple Cancer Types Targeted in $2.5B Opportunity - Stock Titan
Sunshine Biopharma stock hits 52-week low at $1.24 - Investing.com Australia
Sunshine Biopharma stock hits 52-week low at $1.24 By Investing.com - Investing.com India
Sunshine Biopharma (NASDAQ:SBFMW) Trading Down 10.9% – Here’s Why - Defense World
Sunshine Biopharma stock hits 52-week low at $1.85 amid steep decline By Investing.com - Investing.com South Africa
Sunshine Biopharma Closes $2.46 Million Direct Offering - TipRanks
Sunshine Biopharma Secures $2.46 Million in Direct Offering - TipRanks
Sunshine Biopharma Closes $2.5 Million Direct Offering - MarketScreener
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering - ACCESS Newswire
SEC Form 424B5 filed by Sunshine Biopharma Inc. - Quantisnow
Sunshine Biopharma stock hits 52-week low at $1.85 amid steep decline - Investing.com India
Sunshine Biopharma’s K1.1-mRNA-LNP shows promise in HCC mouse model - BioWorld MedTech
The time has not yet come to remove your chips from the table: Sunshine Biopharma Inc (SBFM) - Sete News
Sunshine Biopharma secures $2.46 million in stock offering By Investing.com - Investing.com Canada
Sunshine Biopharma Reports 78% Revenue Growth and Key Developments in 2022 - TipRanks
Sunshine Biopharma (SBFM) Reports Increased Revenue Despite Net Loss - GuruFocus
Sunshine Biopharma (SBFM) Secures $2.46 Million in Direct Stock Offering - GuruFocus
Sunshine Biopharma secures $2.46 million in stock offering - Investing.com
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules - ACCESS Newswire
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug - Benzinga
Biotech Stock Sunshine Biopharma Inc. (NASDAQ:SBFM) Makes NASDAQ Top Gainer List on News - Investorideas.com
This Pharma Stock Is Gaining Major Steam Ahead Of Opening Bell - The Globe and Mail
From Underdog to Top Performer: Sunshine Biopharma’s Impressive Surge - timothysykes.com
Sunshine Biopharma (SBFM) Announces Promising Results for Liver Cancer Treatment - GuruFocus
Sunshine Biopharma reports progress in liver cancer treatment - Investing.com India
Sunshine Biopharma Inc Stock (SBFM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):